DYSLIPIDEMIA DRUG INDICATIONS

DYSLIPIDEMIA DRUG INDICATIONS
Generic Brand Form Indications
Slow
coronary
athero-
sclerosis
Lower
total-C
Lower
LDL-C
Increase
HDL-C
Lower
apo B
Lower
TG
Sitosterol/
campe-
sterol
Reduce
risk of
CVD4
BILE ACID SEQUESTRANTS
cholestyr
amine resin
pwd  
colesevelam Welchol tabs,
oral susp
colestipol Colestid tabs,
granules
CHOLESTEROL ABSORPTION INHIBITOR
ezetimibe Zetia tabs 2
FIBRATES
fenofibrate Antara caps
Fenoglide tabs
Lipofen caps
Lofibra tabs, caps
Tricor tabs
Triglide tabs
fenofibric acid Fibricor tabs
Trilipix del-rel caps
LIPID-REGULATING AGENT
gemfibrozil Lopid scored tabs 1
icosapent ethyl Vascepa caps
omega-3-acid
ethyl esters
Lovaza caps
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITOR
lomitapide mesylate Juxtapid caps 3
NICOTINIC ACID DERIVATIVES
niacin Niaspan ext-rel tabs
OLIGONUCLEOTIDE INHIBITOR
mipomersen Kynamro SC inj 3
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) INHIBITOR
alirocumab Praluent SC inj
evolocumab Repatha SC inj
Repatha Pushtronex SC inj
STATINS (HMG-CoA REDUCTASE INHIBITORS)
atorvastatin Lipitor tabs
fluvastatin Lescol caps
Lescol XL ext-rel tabs
lovastatin tabs
Altoprev ext-rel tabs
pitavastatin Livalo tabs
pravastatin Pravachol tabs
rosuvastatin Crestor tabs 3
simvastatin Zocor tabs
STATIN + CALCIUM CHANNEL BLOCKER
atorvastatin +
amlodipine
Caduet tabs
STATIN + CHOLESTEROL ABSORPTION INHIBITOR
simvastatin +
ezetimibe
Vytorin tabs
Classification of Hyperlipoproteinemias
Fredrickson Type    Elevated Lipoproteins     Lipid Elevations (Major)      Lipid Elevations (Minor)
I (rare) chylomicrons triglycerides total-C elevated or no change
IIa LDL total-C
IIb LDL, VLDL total-C triglycerides
III (rare) IDL total-C/triglycerides
IV VLDL triglycerides total-C elevated or no change
V chylomicrons, VLDL triglycerides total-C elevated or no change
NOTES

Key:  apo B = apolipoprotein B;  TG = triglycerides;  total-C = total cholesterol;  LDL-C = low-density lipoproteins;  CVD = cardiovascular disease;  IDL = intermediate-density lipoproteins;  VLDL = very low density lipoproteins;  HDL-C = high-density lipoproteins

1 Reduction in risk of coronary artery disease when first line agent is inadequate

2 To reduce elevated sitosterol and campesterol in homozygous familial sitosterolemia

3 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

4 To reduce risk of: MI, stroke, or coronary revascularization procedures, and morbidity/mortality.

FDA-approved indications marked with a ✓. Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. Listed indications may be adjuncts to other therapies, lifestyle changes and/or concomitant drugs.

(Rev. 3/2017)

This article originally appeared on MPR